State Street Corp Sells 26,260 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

State Street Corp lessened its holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 2.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 899,379 shares of the company's stock after selling 26,260 shares during the period. State Street Corp owned about 2.36% of Tarsus Pharmaceuticals worth $29,581,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the business. Ikarian Capital LLC increased its holdings in Tarsus Pharmaceuticals by 28.7% during the 3rd quarter. Ikarian Capital LLC now owns 1,030,277 shares of the company's stock worth $33,886,000 after purchasing an additional 230,000 shares in the last quarter. Verition Fund Management LLC bought a new stake in Tarsus Pharmaceuticals during the third quarter worth $763,000. Vestal Point Capital LP purchased a new stake in Tarsus Pharmaceuticals in the 3rd quarter valued at $7,565,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Tarsus Pharmaceuticals by 10.7% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 58,835 shares of the company's stock valued at $1,935,000 after acquiring an additional 5,709 shares in the last quarter. Finally, Ally Bridge Group NY LLC purchased a new position in Tarsus Pharmaceuticals during the 3rd quarter worth $10,587,000. Institutional investors own 90.01% of the company's stock.

Analysts Set New Price Targets

TARS has been the topic of a number of recent analyst reports. William Blair raised shares of Tarsus Pharmaceuticals to a "strong-buy" rating in a research report on Friday, August 30th. Oppenheimer lifted their target price on shares of Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the stock an "outperform" rating in a research report on Thursday, November 14th. Finally, The Goldman Sachs Group upped their target price on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a "neutral" rating in a report on Friday, November 15th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Tarsus Pharmaceuticals has an average rating of "Buy" and a consensus price target of $54.20.

Tarsus Pharmaceuticals Stock Performance

Shares of TARS stock traded up $0.91 during trading hours on Friday, hitting $52.91. 741,534 shares of the company were exchanged, compared to its average volume of 712,735. The company has a current ratio of 5.42, a quick ratio of 5.38 and a debt-to-equity ratio of 0.30. The stock has a market capitalization of $2.02 billion, a price-to-earnings ratio of -13.89 and a beta of 1.04. The firm has a fifty day simple moving average of $46.51 and a 200 day simple moving average of $35.04. Tarsus Pharmaceuticals, Inc. has a 52-week low of $18.99 and a 52-week high of $56.77.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.